Tom 12, Nr 1 (2017)
Artykuł przeglądowy
Opublikowany online: 2016-09-13
Wyświetlenia strony
1739
Wyświetlenia/pobrania artykułu
1314
Pentraksyna 3 jako niezależny marker rozwoju choroby wieńcowej, stopnia jej zaawansowania oraz rokowania
Folia Cardiologica 2017;12(1):55-60.
Streszczenie
Pentraksyna 3 (PTX3) jest białkiem ostrej fazy i, podobnie jak białko C-reaktywne, należy do nadrodziny pentraksyn. Jest produkowana pod wpływem czynników zapalnych przez różnego rodzaju komórki, między innymi związane bezpośrednio z rozwojem miażdżycy, na przykład komórki śródbłonka naczyniowego czy makrofagi, w związku z czym PTX3 postrzega się jako specyficzny marker lokalnego zapalenia. Jest białkiem odzwierciedlającym proces zapalny w chorobach układu sercowo-naczyniowego, włączając bezobjawową miażdżycę, stabilną chorobę wieńcową, ostre zespoły wieńcowe (ACS) i niewydolność serca. Związek PTX3 z czynnikami ryzyka sercowo-naczyniowego pozwala sądzić, że jest ona obiecującym parametrem oceny rozwoju miażdżycy. Dotychczasowe badania sugerują, że może być ona przydatnym markerem w diagnostyce ACS. Co ważne, u pacjentów po już przebytym incydencie wieńcowym czy też u chorych z niewydolnością serca PTX3 okazała się niezależnym czynnikiem niekorzystnego rokowania.
Słowa kluczowe: pentraksyna 3miażdżycablaszki miażdżycoweczynniki ryzyka sercowo-naczyniowegoostry zespół wieńcowyniewydolność serca
Referencje
- Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006; 45(5): 326–330.
- Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992; 267(31): 22190–22197.
- Han B, Mura M, Andrade CF, et al. TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol. 2005; 175(12): 8303–8311.
- Introna M, Alles VV, Castellamo M, et al. Cloning of mouse extrahepatic sites. Blood. 1996; 87(5): 1862–1872.
- Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007; 204(4): 793–804.
- Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002; 420(6912): 182–186.
- Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003; 33(2): 465–473.
- Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102(6): 636–641.
- Latini R, Maggioni AP, Peri G, et al. Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110(16): 2349–2354.
- Tazaki R, Tanigawa J, Fujisaka T, et al. Plasma pentraxin 3 level is associated with plaque vulnerability assessed by optical coherence tomography in patients with coronary artery disease. Int Heart J. 2016; 57(1): 18–24.
- Jenny NS, Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009; 29(4): 594–599.
- Yano Y, Matsuda S, Hatakeyama K, et al. Plasma pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci. 2010; 65(5): 547–552.
- Ohbayashi H, Miyazawa C, Miyamoto K, et al. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009; 16(4): 490–500.
- Jylhävä J, Haarala A, Kähönen M, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol. 2011; 164(2): 211–217.
- Zanetti M, Bosutti A, Ferreira C, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009; 9(3): 243–248.
- Yamasaki K, Kurimura M, Kasai T, et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009; 47(4): 471–477.
- Rashtchizadeh N, Ghaffari M, Sede SA, et al. Associations of pentraxin 3 with presence and severity of coronary artery disease in type 2 diabetes patients. Turk J Biochem. 2015; 40(1): 37–43.
- Jenny NS, Blumenthal RS, Kronmal RA, et al. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2014; 12(6): 999–1005.
- Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007; 27(1): 161–167.
- Dubin R, Li Y, Ix JH, et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012; 163(2): 274–279.
- Ogawa T, Kawano Y, Imamura T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010; 18(9): 1871–1874.
- Barazzoni R, Aleksova A, Carriere C, et al. Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome. Cardiovasc Diabetol. 2013; 12: 167.
- Tomandlova M, Jarkovsky J, Tomandl J, et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers. 2015; 2015: 159051.
- Koga S, Ikeda S, Yoshida T, et al. Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv. 2013; 6(9): 945–954.
- Vuković-Dejanović V, Bogavac-Stanojević N, Spasić S, et al. Association of serum pentraxin-3 and high-sensitivity C-reactive protein with the extent of coronary stenosis in patients undergoing coronary angiography. J Med Biochem. 2015; 34(4): 440–449.
- Liu H, Guan S, Fang W, et al. Associations between pentraxin 3 and severity of coronary artery disease. BMJ Open. 2015; 5(4): e007123.
- Klouche M, Peri G, Knabbe C, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004; 175(2): 221–228.
- Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120(8): 699–708.
- Camozzi M, Zacchigna S, Rusnati M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005; 25(9): 1837–1842.
- Brambilla M, Camera M, Colnago D, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol. 2008; 28(5): 947–953.
- Santilli F, Guagnano MT, Innocenti P, et al. Pentraxin 3 and platelet activation in obese patients after gastric banding. Circ J. 2016; 80(2): 502–511.
- Kume N, Mitsuoka H, Hayashida K, et al. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol. 2011; 58(1): 38–45.
- Latini R, Gullestad L, Masson S, et al. Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012; 14(9): 992–999.
- Kimura S, Inagaki H, Haraguchi Go, et al. Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. Circ J. 2014; 78(1): 159–169.
- Guo R, Li Y, Wen J, et al. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology. 2014; 129(3): 178–188.
- Matsui S, Ishii J, Kitagawa F, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010; 210(1): 220–225.
- Miyazaki T, Chiuve S, Sacks FM, et al. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One. 2014; 9(4): e94073.
- Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008; 155(1): 75–81.
- Saygı S, Kırılmaz B, Tengiz İ, et al. Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting. Turk Kardiyol Dern Ars. 2012; 40(3): 205–212.
- Matsubara J, Sugiyama S, Nozaki T, et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc. 2014; 3(4).
